Isoliquiritigenin Attenuates Monocrotaline-Induced Pulmonary Hypertension via Inhibition of the Inflammatory Response and PASMCs Proliferation

<p>Effects of ISL on pulmonary artery structural remodeling. (a) Hematoxylin and eosin staining of pulmonary arteries (scale bar = 50 <i>μ</i>m). (b) Medial wall thickness (WT%) of pulmonary arteries. (c) Medial wall area (WA%) of pulmonary arteries. Values are means ± SEM (<i>n</i> = 8). <sup>##</sup><i> p</i> &lt; 0.01, compared with saline group; <svg height="12.2304pt" id="M7" style="vertical-align:-0.04990005pt" version="1.1" viewbox="-0.0498162 -12.1805 4.98213 12.2304" width="4.98213pt" xmlns="http://www.w3.org/2000/svg"><g transform="matrix(.0091,0,0,-0.0091,0,-5.741)"><path d="M263 363V584C343 572 363 521 380 464L408 470C399 526 392 562 387 596C376 598 367 601 353 604C328 612 296 617 263 617V693H228V615C122 603 67 532 67 453C67 376 123 329 193 300L228 284V41C132 52 93 131 75 189L45 181C54 130 66 71 73 50C113 24 170 9 228 9V-76H263V11C370 24 434 90 434 185C434 275 367 325 292 352L263 363ZM228 376C171 398 136 431 136 484C136 530 164 578 228 584V376ZM263 272L275 267C345 236 359 196 359 150C359 96 325 50 263 42V272Z"></path></g></svg><i> p</i> &lt; 0.05, compared with MCT group.</p>

Evidence-Based Complementary and Alternative Medicine

fig2

Figure 2

Figure 2: Isoliquiritigenin Attenuates Monocrotaline-Induced Pulmonary Hypertension via Inhibition of the Inflammatory Response and PASMCs Proliferation 

Figure 2 | Isoliquiritigenin Attenuates Monocrotaline-Induced Pulmonary Hypertension via Inhibition of the Inflammatory Response and PASMCs Proliferation 